ClinicalTrials.gg
CompletedNCT03980080Updated Dec 12, 2019

Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects

A Phase 1 interventional study of OSE-127 and Placebo in Healthy Subjects, sponsored by OSE Immunotherapeutics. Completed at 1 site in Belgium. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-12.

Sponsored by OSE Immunotherapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2018, registered May 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Inflammatory Bowel Diseases with a site in Belgium — 13 open to participants now, 18 under way, 5 of them phase 3. Inflammatory Bowel Diseases · Belgium.

Enrollment
40th of 50
63 · median 144
Started
2018
with 3 others
Phase 1
4 of 61
none open now
Registered
32nd of 61
by date
Lead sponsor
2 of 61
OSE Immunotherapeutics

Among the 61 studies in Inflammatory Bowel Diseases with a site in Belgium, this one is the 40th largest by enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2018, is one of 4 in phase 1, and was the 32nd registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

13 of the 61 studies in Inflammatory Bowel Diseases with a site in Belgium are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Inflammatory Bowel Diseases with a site in Belgium, or all of them as a file.
02

Study summary

This study is a first-in-human phase I randomised, double-blind, placebo-controlled, evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single (IV and SC) and Multiple (IV only) Ascending Doses of OSE-127 in Healthy Subjects.

03

Conditions studied

  • Healthy Subjects

Keywords

  • CD127/IL-7Rα Antagonist
  • Auto-Immune Diseases
  • inflammatory bowel diseases
  • Ulcerative Colitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged 18 to 65 years (extremes included). Maximum two subjects aged between 60 and 65 (extremes included) are allowed per dose group.
  2. Healthy volunteers (medically stable), as determined on the basis of medical history, vital signs, clinical laboratory testing, and general physical examination performed at screening and deemed appropriate by the Investigator.
  3. (ECG) within normal range, or showing no deviations, as judged by the Investigator.
  4. Weighs at least 50 kg and no more than 100 kg and has a (BMI) within normal range: 19.0 ≤ BMI ≤ 30.0 kg/m².
  5. Negative urine test for selected drugs of abuse at screening.
  6. Negative alcohol breath test at screening.
  7. Female subjects is , surgically sterile (having had a hysterectomy or bilateral oophorectomy) and/or is using a highly effective method of (from 2 weeks before first study drug administration until 28 days after the last follow-up visit, when it is confirmed that the RO of the subject \<20% or 5 t1/2 whichever is longer).
  8. Female subject has a negative pregnancy test at screening.
  9. Non-vasectomized male subjects having a female partner of must agree to the use of a highly effective method of contraception (from the first study drug administration until 28 days after the last follow-up visit, when it is confirmed that the RO of the subject \<20% or 5 t1/2 whichever is longer).
  10. Willing to adhere to the prohibitions and restrictions specified in the protocol.
  11. Form (ICF) signed voluntarily before any study-related procedure is performed, indicating that the subject understands the purpose of and procedures required for the study and is willing to participate in the study.
  12. Non-smoker or light smoker, i.e. smokes maximal 5 cigarettes (or 3 cigars or 3 pipe-full) per day, and ability and willingness to refrain from smoking during confinement and ambulant visits in the CPU.

Exclusion criteria

Exclusion Criteria:

  1. A history of any (as determined by the Investigator) cardiac, endocrinology, hematology, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or excluding non-melanoma skin cancer.
  2. A known allergy, , or intolerance to any of the in the formulation of the study drug.
  3. The subject has a history of severe allergic or anaphylactic reactions.
  4. The suject has a history of consuming more than 14 units of alcoholic beverages per week for male subjects, and more than 10 units for females. Or a history of alcoholism, or drug/chemical/substance abuse within the past 2 years prior to screening.
  5. Evidence or history of any clinically significant infections within the past 3 months.
  6. Subject with known clinically relevant immunological disorders, or auto-immune disorders (e.g. rheumatoid arthritis, lupus erythematosus, scleroderma, etc...).
  7. A positive hepatitis panel (including surface antigen [HBsAg] and anti- virus [HCV] antibodies [Abs]) or positive (HIV) antibody screens.
  8. The subject has a supine systolic blood pressure (SBP) \<90 or >149 mmHg and/or a diastolic blood pressure (DBP) \<45 or >90 mmHg, and/or a pulse rate higher than 100 beats per minute (bpm) at screening (blood pressure measurements taken after subject has been resting in a supine position for a minimum of 5 minutes).
  9. Pregnant or breastfeeding women.
  10. The subject has received a (excluding flu vaccination), within 30 days prior to study drug administration, or plan to receive this type of vaccine during the study.
  11. The subject has received any systemic agent, within 6 months prior to study drug administration.
  12. The subject has received any antibody or biologic medicinal product, within 6 months prior to study drug administration.
  13. The subject has received any systemic , within 2 months prior to study drug administration.
  14. Use of a prohibited therapy during the study.
  15. Receipt of any drug, within 30 days or 5 half-lives (whichever is longer) prior to the initial study drug administration.
  16. The subject is participating in another clinical trial or has participated in another dose group of the current trial. Participation in non-interventional registries or epidemiological studies is allowed.
  17. Having had a significant blood loss (including blood donation [>500 mL]) or a having had a transfusion of any blood product (within the past 60 days) or donated plasma (within 7 days prior to the initial study drug administration).
  18. A condition that, in the opinion of the Investigator, could compromise their well-being or the course of the study, or prevent them from meeting or performing any study requirement.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    OSE-127: Part 1 (SAD), Cohort A & Cohort B

    Drug: OSE-127

  • Placebo comparator
    Placebo: Part 1 (SAD), Cohort A & Cohort B

    Drug: Placebo

  • Experimental
    OSE-127: Part 2 (MAD)

    Drug: OSE-127

  • Placebo comparator
    Placebo: Part 2 (MAD)

    Drug: Placebo

Interventions

  • DrugOSE-127

    mAb antagonist to CD127 receptor (or IL-7Rα) Group 1-7 6 escalating dose level groups IV SC

  • DrugPlacebo

    Vehicle study drug

  • DrugOSE-127

    mAb antagonist to CD127 receptor (or IL-7Rα) Group 8-9 2 escalating dose level groups IV

06

What researchers measure

Primary outcomes

  1. Part 1 (SAD) & Part 2 (MAD) : Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: 12 weeks (for Part 1); 19 weeks (for Part 2)

  2. Part 1 (SAD) & Part 2 (MAD) : Number of Participants With Clinically Significant Findings in Physical Examinations Reported as Adverse Event

    Time frame: 12 weeks (for Part 1); 19 weeks (for Part 2)

  3. Part 1 (SAD) & Part 2 (MAD) : Number of Participants With Clinically Significant Change in Clinical Laboratory Results Reported as Adverse Event

    Time frame: 12 weeks (for Part 1); 19 weeks (for Part 2)

  4. Part 1 (SAD) & Part 2 (MAD) :Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) Reported as Adverse Event

    Time frame: 12 weeks (for Part 1); 19 weeks (for Part 2)

  5. Part 1 (SAD) & Part 2 (MAD) :Number of Participants With Clinically Significant Change in vital signs Reported as Adverse Event

    Time frame: 12 weeks (for Part 1); 19 weeks (for Part 2)

  6. Part 1 (SAD) & Part 2 (MAD) :Number of Participants With Clinically Significant Findings in Telemetry Reported as Adverse Event

    Time frame: 12 weeks (for Part 1); 19 weeks (for Part 2)

  7. Part 1 (SAD) & Part 2 (MAD) : Incidence of anti-drug antibody (ADA) formation

    Time frame: 12 weeks (for Part 1); 19 weeks (for Part 2)

Secondary outcomes

  1. Part 1 (SAD) & Part 2 (MAD) : Maximum Plasma Concentration [Cmax]

    Time frame: 12 weeks (for Part 1); 19 weeks (for Part 2)

  2. Part 1 (SAD) & Part 2 (MAD) : Average serum Concentration over the dosing interval [Cavg]

    Time frame: 12 weeks (for Part 1); 19 weeks (for Part 2)

  3. Part 1 (SAD) & Part 2 (MAD) : Trough serum Concentration observed at the end of the dosing interval [Ctrough]

    Time frame: 12 weeks (for Part 1); 19 weeks (for Part 2)

  4. Part 1 (SAD) & Part 2 (MAD) : Elimination half-life associated with the terminal rate constant (λz) [T1/2]

    Time frame: 12 weeks (for Part 1); 19 weeks (for Part 2)

  5. Part 1 (SAD) & Part 2 (MAD) : Time corresponding to the Cmax [Tmax]

    Time frame: 12 weeks (for Part 1); 19 weeks (for Part 2)

  6. Part 1 (SAD) & Part 2 (MAD) : Area Under the serum concentration-time Curve from time zero till X days postdose [AUCτ]

    Time frame: 12 weeks (for Part 1); 19 weeks (for Part 2)

  7. Part 1 (SAD) & Part 2 (MAD) : AUC calculated between time of administration and last quantifiable concentration [AUClast]

    Time frame: 12 weeks (for Part 1); 19 weeks (for Part 2)

  8. Part 1 (SAD) & Part 2 (MAD) : AUC extrapolated to infinity [AUCinf]

    Time frame: 12 weeks (for Part 1); 19 weeks (for Part 2)

  9. Part 1 (SAD) & Part 2 (MAD) : AUC over the dosing interval [AUC0-τ].

    Time frame: 12 weeks (for Part 1); 19 weeks (for Part 2)

  10. Part 1 (SAD) & Part 2 (MAD) : Accumulation Ratio [Rac].

    Time frame: 12 weeks (for Part 1); 19 weeks (for Part 2)

  11. Part 1 (SAD) & Part 2 (MAD) : CD-127 Receptor Occupancy [RO]

    Time frame: 12 weeks (for Part 1); 19 weeks (for Part 2)

  12. Part 1 (SAD) & Part 2 (MAD) : Effect on total lymphocyte count

    Time frame: 12 weeks (for Part 1); 19 weeks (for Part 2)

07

Study locations

1 site
  • SGS Life Sciences (SGS LS), Clinical Pharmacology Unit (CPU)
    Antwerp, 2060, Belgium
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Nov 2019, 10 months.

Of 35 industry-sponsored phase 1 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 10 months is above that.

Counting every sponsor, half of 51 studies reached it within 12 months; a quarter within 4 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2019
First posted
Jun 10, 2019
StartActual
Dec 19, 2018
Primary completionActual
Nov 4, 2019
CompletionActual
Nov 4, 2019
Last update
Dec 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03980080
Lead sponsor
OSE Immunotherapeutics
Collaborators
Servier
Responsible party
Sponsor
First posted
Jun 10, 2019
Start date
Dec 19, 2018
Primary completion
Nov 4, 2019
Completion
Nov 4, 2019
Last update
Dec 12, 2019

Study contacts

Frédérique Corallo, MD
study director · OSE Immunotherapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion